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Background. Literature on recovery of kidney function (RKF) in patients with end-stage kidney 
disease treated with maintenance dialysis (i.e. over 90 days) is limited. We assessed the incidence of 
RKF and its associated characteristics in a European cohort of dialysis patients.
Methods. We included adult patients from the European Renal Association-European Dialysis and 
Transplant Association (ERA-EDTA) Registry who started maintenance dialysis in 1997-2016. 
Sustained RKF was defined as permanent discontinuation of dialysis. Temporary discontinuation of 
≥30 days (non-sustained RKF) was also evaluated. Factors associated with RKF adjusted for potential 
confounders were studied using Cox-regression analyses. 
Results. RKF occurred in 7,657 (1.8%) of 440,996 patients of whom 71% experienced sustained RKF. 
Approximately 90% of all recoveries occurred within the first two years after day 91 of dialysis. Of 
patients with non-sustained RKF, 39% restarted kidney replacement therapy within one year. 
Sustained RKF was strongly associated with the following underlying kidney diseases (as registered 
by the treating physician): tubular necrosis (irreversible) or cortical necrosis (adjusted Hazard Ratio 
[aHR]: 20.4, 95%CI: 17.9-23.1), systemic sclerosis (aHR: 18.5, 95%CI: 13.8-24.7) and hemolytic 
uremic syndrome (aHR: 17.3, 95%CI: 13.9-21.6). Weaker associations were found for hemodialysis as 
first dialysis-modality (aHR: 1.5, 95%CI: 1.4-1.6) and dialysis initiation at an older age (aHR: 1.8, 
95%CI: 1.6-2.0) or in a more recent time-period (aHR: 2.4, 95%CI: 2.1-2.7). 
Conclusions. Definitive discontinuation of maintenance dialysis is a rare and not necessarily an early 
event. Certain clinical characteristics, but mostly the type of underlying kidney disease, are associated 
with a higher likelihood of RKF. 










What is already known about this subject?
- The incidence of recovery of kidney function (RKF) in patients treated with maintenance 
dialysis varies in the literature, possibly due to varying definitions of ESKD and RKF
- Hence, the incidence might be overestimated due to inclusion of patients with acute kidney 
injury (AKI) instead of ESKD or by inclusion of patients who could only temporarily 
discontinue dialysis treatment (i.e. non-sustained RKF)
What this study adds?
- This study shows a 1.2% incidence of sustained RKF in patients who have been treated with 
maintenance dialysis for at least 90 days
- Sustained RKF is not necessarily an early event, as nearly half of the patients experienced 
sustained RKF after at least one year of maintenance dialysis
- Sustained RKF is most prevalent in patients with certain underlying primary kidney diseases, 
such as tubular necrosis (irreversible) or cortical necrosis, systemic sclerosis and hemolytic 
uremic syndrome. 
What impact this may have on practice or policy?
- Clinicians should be vigilant for RKF in patients treated with maintenance dialysis, not only in 
the first few months after initiation of the treatment.
- This is of particular importance in a patient with an underlying kidney disease which is 










Although end-stage kidney disease (ESKD) generally describes irreversible kidney failure requiring 
kidney replacement therapy (KRT), a small percentage of patients treated with maintenance dialysis 
(i.e. dialysis for more than 90 days) experience recovery of kidney function (RKF). This can result in a 
reduction of dialysis dose or even permanent discontinuation of dialysis treatment. 
Data on the incidence of RKF in patients treated with maintenance dialysis in Europe are limited to 
small case series (1,2), single-center (3,4) and single-country studies (5). Reports from observational 
studies and registries in other parts of the world show that RKF occurs in 1.0 to 6.7% of dialysis 
patients (6-10). However, these studies express large heterogeneity regarding the definitions used for 
ESKD and RKF, respectively. Several studies describe RKF to occur within the first 90 days of 
dialysis treatment, thereby probably including a substantial number of patients with acute kidney 
injury (AKI) rather than ESKD. Moreover, previous studies include both patients with sustained 
recoveries, i.e. permanent discontinuation of KRT and patients who had to recommence KRT after 
variable, sometimes very short-lived KRT-free intervals. Hence, literature on the incidence and 
associated clinical characteristics of definitive discontinuation of maintenance dialysis in patients with 
ESKD is currently limited to a report from the Australian and New Zealand Dialysis and Transplant 
(ANZDATA) Registry published in 2009. In that study, RKF was found to occur in 1% of the 
approximately 40,000 individuals treated with maintenance dialysis between 1963 and 2006 (7). 
Therefore, we assessed the incidence of sustained, as well as non-sustained RKF, and its associated 
demographic and clinical characteristics in a large cohort of patients with ESKD treated with 











Data of patients with ESKD aged 20 years or older who started dialysis as their first KRT modality 
between 1997 and 2016 and who received maintenance dialysis treatment, i.e. dialysis for at least 90 
days, were extracted from the European Renal Association – European Dialysis Transplantation 
Association (ERA-EDTA) Registry database. Follow-up continued until December 31st, 2017. 
The ERA-EDTA Registry annually collects individual data of patients starting KRT from national and 
regional renal registries in Europe. Methods of data collection and processing are described in detail 
elsewhere (11). Data from the following 27 registries were included: Austria, Dutch-speaking 
Belgium, French-speaking Belgium, Bosnia and Herzegovina, Denmark, Finland, France, Greece, 
Iceland, the Netherlands, Norway, the Spanish regional renal registries of Andalusia, Aragon, 
Asturias, Basque Country, Cantabria, Castile and León, Castile-La Mancha, Catalonia, Extremadura, 
Galicia, Community of Madrid, Murcia, Valencia (inclusion until 2015, follow-up until December 
31st, 2016); Sweden, UK (England, Northern Ireland and Wales) and UK (Scotland). National and 
regional registries contributing data to the ERA-EDTA Registry complied with national legislation 
with regard to ethics committee approval. We extracted the following patient characteristics: age, sex, 
dialysis modality at onset, dialysis modality at day 91, country of residence and underlying kidney 
disease, coded as primary renal disease (PRD). The latter was recorded by the responsible physician 
and classified according to the coding system of the ERA-EDTA (11). We grouped these PRD codes 
into twenty PRD categories, as shown in Supplementary Table 1. The dataset contained no missing 
values for month or year of birth, sex, or dialysis modality and in case of PRD, 0.9% of values were 
missing.
Recovery of kidney function
RKF was defined as a discontinuation of maintenance dialysis while remaining alive for at least 30 
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at least 30 days of KRT-free survival. Patients who returned to KRT within the follow-up period after 
a KRT-free interval of at least 30 days were considered to have experienced non-sustained RKF. 
Follow-up
Patients were followed from Day 91 of dialysis treatment until any of the following events: RKF, 
kidney transplantation, loss to follow-up, death or end of study period (December 31, 2017). As 
patients were included from December 1996 until 31 December 2015, potential follow-up was at least 
2 years.
Statistical analyses
Data are presented as percentages for categorical variables or as means with standard deviation or 
median with interquartile range (IQR; 25th-75th percentile) for continuous variables. To study 
differences between groups, P-values were calculated using Chi-square tests for categorical variables 
and Wilcoxon tests for continuous variables.
We used the cumulative incidence competing risk approach to study time from day 91 of dialysis to 
RKF, in which kidney transplantation, loss to follow-up, death and end of study period were taken into 
account as competing events (12). Unadjusted and adjusted Cox regression analyses were used to 
determine factors associated with RKF. The variables included in the adjusted models were age, sex, 
year of onset of dialysis, dialysis modality at day 91, underlying kidney disease and country of 
residence. In addition, we used the cumulative incidence competing risk approach to study time from 
day 31 after RKF to death, restart of dialysis or kidney transplantation. In all analyses, follow-up time 
was censored at five years or at the end of the study period (31 December 2017).
To explore trends over time in the occurrence of RKF, the incidence of RKF was evaluated by 
dividing the number of RKF cases among patients starting dialysis in each year by the total number of 
incident dialysis patients in that year. As in our dataset 90% of recoveries occurred within two years 
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follow-up time for RKF to occur. For these analyses, we only included data from registries with 
available data for the complete time-period 1997-2015. The slope of the trends, i.e. the annual 
percentage change (APC), was computed using Poisson regression as provided by the Joinpoint 
regression program 4.0.4. Details of this method have been previously described (13). Statistical 












Our cohort comprised 440,996 patients who started maintenance dialysis (i.e. dialysis for more than 90 
days) between 1997 and 2016 (Table 1). A total of 7,657 patients (1.8%) were reported to have 
experienced RKF that lasted for at least 30 days. The majority of these patients (N=5,465; 71%) 
experienced sustained RKF. Their characteristics, as well as those of patients with a non-sustained 
RKF are listed in Table 1. 
Patients with sustained RKF were older, more often female and more frequently initiated KRT with 
hemodialysis, as compared with patients with non-sustained RKF (Table 1). Patients with non-
sustained RKF recommenced KRT after various KRT-free intervals; 39% of patients restarted KRT 
within one year and 60% within two years after discontinuation of maintenance dialysis (Table 1). 
Characteristics associated with recovery of kidney function
Underlying kidney disease - After adjustment for age at start of dialysis, sex, treatment modality at day 
91, country of residence and time period of dialysis initiation, patients with the following PRD codes 
had the highest likelihood of experiencing sustained RKF as compared to patients with diabetes 
mellitus (reference group): tubular necrosis (irreversible) or cortical necrosis (adjusted hazard ratio 
[aHR] 20.35, 95% CI: 17.89-23.14), systemic sclerosis (aHR 18.50, 95% CI: 13.84-24.72), hemolytic 
uremic syndrome (HUS) (aHR 17.31, 95% CI: 13.88-21.59), paraproteinemia (aHR 7.96, 95% CI: 
7.04-9.01), vasculitis (aHR 5.72, 95% CI: 4.96-6.59) and ischaemic renal disease/cholesterol 
embolism (aHR 4.15, 95% CI: 3.46-4.98). The lowest likelihood of sustained RKF was found in 
patients with cystic kidney disease (aHR 0.11, 95% CI: 0.07-0.19) and congenital kidney disease (aHR 
0.67, 95% CI: 0.39-1.14). The findings were consistent when patients with non-sustained RKF were 
included (Table 2). 
Other characteristics - Female sex (aHR 1.13, 95% CI: 1.07-1.19), onset of dialysis treatment at age 
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treatment modality (aHR 1.50, 95% CI: 1.38-1.64) and dialysis initiation in a more recent time period 
(aHR 2.38, 95% CI: 2.14-2.65) were also significantly associated with a higher likelihood of sustained 
RKF, although to a lesser extent than the aforementioned underlying kidney diseases (Table 2). These 
observations were consistent when patients with non-sustained RKF were included, except for patients 
older than 80 years at the initiation of dialysis (Table 2). 
Recovery of kidney function: incidence and trends over time 
Figure 1 displays the cumulative incidence of RKF (1.8%) and of the competing events death (48.7%), 
kidney transplantation (22.6%) and loss to follow-up (0.9%) in the five years from day 91 of dialysis. 
The distribution of time on maintenance dialysis before RKF is depicted in Figures 2A and 2B. 
Approximately 90% of all RKF occurred within the first two years after day 91 of dialysis. Median 
time on maintenance dialysis before non-sustained RKF was 265 days [IQR: 153-510] and 237 days 
[137-464] for patients with sustained RKF, respectively. 
As presented in Figure 3, we observed a statistically significant increase in the incidence of RKF in the 
years 1997-2007 with an APC of 6.5 (95% CI: 5.1 to 7.9). Between 2007 and 2012 the incidence of 
RKF was stable over time, and declined in the years 2012-2015 (APC: -10.3 (95% CI: -17.6 to -2.4)). 
The proportion of patients with a kidney disease with a high likelihood of RKF remained stable over 
the time period 1997-2015 (data not shown).
The time to RKF varied markedly according to the type of underlying kidney disease (Supplementary 
Figure 1). Across all PRD categories, the incidence of RKF was highest in the first 9 months after 
initiation of maintenance dialysis (Figure 2), although patients with vasculitis and ischaemic renal 
disease/cholesterol embolism showed a more stable, although very low, incidence rate of RKF over 
time.
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The cumulative incidence of death and return to KRT in the five years after day 31 of RKF is shown in 
Figure 4; 55% did not have a subsequent event within the follow-up period, and are thus considered as 
sustained RKF, 15.7% died, 28.1% recommenced dialysis treatment and 1.2% underwent kidney 
transplantation. Among the underlying kidney diseases with the highest likelihood of RKF, the 
percentage of patients who did not restart KRT after RKF was 74% for patients with tubular necrosis 
(irreversible) or cortical necrosis, 79% for systemic sclerosis, 73% for HUS and 65% for patients with 
paraproteinemia. However, among patients with vasculitis and ischaemic renal disease/ cholesterol 
embolism, the proportion with sustained RKF, 59% and 61% respectively, was more in line with the 










This study shows that permanent discontinuation of maintenance dialysis occurs in 1.2% of ESKD 
patients in Europe across a variety of underlying kidney diseases, although patients with PRD 
categories tubular necrosis (irreversible) or cortical necrosis, systemic sclerosis and HUS have the 
highest likelihood of RKF. More than half of the sustained RKF occurred within one year after day 91 
of dialysis, showing that sustained RKF is not necessarily an early event. Moreover, the time point at 
which RKF occurred was found to differ between the types of underlying kidney disease. 
Although the observed incidence of RKF is in line with the average of 1% reported in case series and 
registries in 2000-2013 (9), these former reports display a large heterogeneity in definitions of ESKD, 
and follow-up time and thereby observed duration of RKF. A recent study that included 194,000 
individuals in the US Medicare ESRD program found sustained dialysis-independent RKF to occur in 
> 5% of patients, primarily in the first two months after initiation of dialysis (8). That study was 
limited by a follow-up time of 2 years at most and included all patients who started dialysis instead of 
only those remaining on dialysis after 91 days, thereby likely comprising a substantial number of 
patients who potentially became dialysis-independent by recovering from AKI (8). By exclusive 
inclusion of patients with ESKD as currently defined (14), we have attempted to minimize the 
possibility of AKI underlying the temporary need for KRT. In other smaller studies in patients with 
ESKD defined as such, incidence of RKF varied from 0.8 to 4% (3,6,7,15). Of these, the study by 
MacDonald and coworkers of the ANZDATA Registry was the largest and most comparable with the 
present study, reporting RKF to occur in 1.1% of the 15,912 individuals treated with peritoneal 
dialysis (PD) and 1.0% of 23,658 patients treated with hemodialysis (HD) between 1963 and 2006 (7). 
In that study, RKF occurred after approximately one year. Twenty-one percent of recovered patients 
died within a year after RKF; 57% returned to KRT and 22% were alive with dialysis-independent 
kidney function at the end of that study. By contrast, we found a lower mortality of 15.7% after five 
years, with a substantially greater number of recovered patients (55%) who did not return to KRT until 
end of follow-up. Moreover, merely 28% of recovered patients returned to KRT in our study, as 
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our current study and that of the ANZDATA Registry. The observed differences in dialysis-free 
survival after RKF are not likely to be explained by the longer follow-up time in that study, as in our 
study, merely 1-2% of the patients with a non-sustained RKF required restart of KRT after five years 
of dialysis discontinuation. Hence, this relatively small number of patients would be insufficient to 
fully explain the difference. Other potential explanations are geographical differences in treatment 
strategies or the larger cohort and the more recent era in our study. Although the rate of RKF in the 
ANZDATA Registry did not change when analyses were restricted to patients starting dialysis from 
1996 (7), we did find an increase in the incidence of RKF over time, which was significant for the 
years 1997-2007. This trend was also observed in the USRDS database (17,18) and in a smaller single 
country study (4). Whether the observed rise in incidence of RKF over time merely reflects changes in 
coding practices by physicians, variations over time in the practice of early versus late start of dialysis, 
or true increments by means of improved treatment strategies for certain kidney diseases, remains to 
be established. Finally, we observed a decline in the incidence of RKF in the years 2012-2015, 
however additional data over a longer period of time are needed to confirm whether this trend is truly 
significant. 
Several studies have shown that the underlying kidney disease is the most important factor associated 
with RKF (6,7,15,18,19). This is in line with our findings, as patients with PRD codes tubular necrosis 
(irreversible) or cortical necrosis, systemic sclerosis and HUS had the highest likelihood of RKF, 
followed by patients with paraproteinemia, vasculitis and ischaemic renal disease/cholesterol 
embolism. By contrast, patients with congenital or cystic kidney disease expressed the lowest 
likelihood of RKF. This also applied to patients with diabetes mellitus. Our finding that the PRD 
categories systemic sclerosis, tubular necrosis (irreversible) or cortical necrosis, HUS and 
paraproteinemia were associated with a higher incidence of RKF is consistent with previous reports 
(6,7,15). This is also in line with clinical practice experience, as patients with these underlying kidney 
diseases often present with acute kidney injury with possible treatment options to restore kidney 
function (20). In a subgroup analysis of auto-immune diseases in the ANZDATA Registry (6,7) RKF 
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vasculitis and a higher likelihood of RKF. In turn, we could confirm their observed positive 
association between interstitial nephritis and RKF (7), although in our analyses the association was not 
as strong as previously reported (data not shown). Multiple myeloma (21,22), systemic sclerosis (23-
24) and HUS (5) were associated with a higher likelihood of RKF in earlier smaller observational 
studies, which is also consistent with our current findings. 
In the present study, female sex, hemodialysis, onset of dialysis at an older age and initiation of 
dialysis in a more recent era were also associated with a higher likelihood of RKF, although to a far 
lesser extent than the underlying kidney disease. A possible explanation for the observed negative 
association between age at dialysis onset and the occurrence of RKF is that in younger patients, 
congenital, cystic and diabetic disease might be overrepresented. These kidney diseases are associated 
with a low likelihood of RKF. In addition, older patients might be more likely to experience pre-
ESKD AKI, due to a higher prevalence of heart failure or cardio-renal syndrome in these older 
patients. Age and sex have been associated with RKF in observational studies employing different 
definitions of ESKD and RKF (9,10). However, in the ANZDATA Registry, after adjustment for 
comorbidities, smoking and body mass index, there was no statistically significant independent 
association of RKF with age, sex, or type of comorbidity (6). Finally, we found a higher likelihood of 
RKF in patients treated with hemodialysis as compared to peritoneal dialysis. A possible explanation 
for this association might be that patients who become dialysis-dependent due to AKI, whether or not 
superimposed on an underlying kidney disease, usually start on HD rather than PD. Existing data 
comparing RKF in HD and PD are inconclusive (10). The ANZDATA Registry showed that dialysis 
modality had no relationship with the rate, timing, or durability of the RKF (7). Hence, the difference 
with our findings is either explained by more extensive adjustment for possible confounders in that 
study or by geographical and historical differences between our study and those of the ANZDATA 
Registry (7). 
Our study has several limitations. Firstly, information on race, body mass index, comorbidities (heart 
failure or cardio-renal syndrome in particular), use of medication, such as renin-angiotensin-
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type of vascular access, delivered dialysis dose and measurements of residual kidney function at time 
of dialysis onset or during maintenance dialysis were unavailable. Due to the lack of these data, we 
could not adjust our analyses for these potentially relevant factors. Secondly, although we exclusively 
included patients with ESKD, it is possible that a considerable number of included patients became 
maintenance dialysis-dependent due to AKI rather than progression of their kidney disease. In a 
retrospective cohort of 47,341 incident hemodialysis patients, 54% had experienced at least one AKI 
event in the two years prior to ESKD (25). Moreover, in that study, 1-year all-cause mortality was 
higher in the pre-ESKD AKI group as compared to the non-AKI group (adjusted odds ratio 1.36; 95% 
CI 1.30-1.42). Since we do not have data on pre-ESKD AKI events, presence of cardio-renal 
syndrome, use of nephrotoxic medications, or serum creatinine slopes in the time prior to initiation of 
KRT, it is impossible to investigate to what extent possible pre-ESKD AKI-events have influenced the 
observed incidence of RKF or mortality in our study. Furthermore, within the ERA-EDTA Registry, 
we can only rely on the kidney disease as coded by the treating physicians, according to pre-specified, 
not necessarily histologically proven, PRD codes. Hence, it is conceivable that patients and 
particularly those registered with PRD code: ‘Tubular necrosis (irreversible) or cortical necrosis’ 
indeed experienced AKI. Notwithstanding, approximately half of these patients experienced RKF after 
one year of dialysis treatment. This supports the message of the current study that AKI, whether or not 
superimposed on an underlying PRD, might still result in RKF even after a long duration of 
maintenance dialysis.
Thirdly, as information on patients who permanently discontinued KRT might be incomplete, the 
mortality rate after permanent discontinuation of KRT (sustained RKF) might be underestimated. Yet, 
we consider it unlikely that many patients who were qualified as having experienced sustained RKF, 
discontinued dialysis in order to pursue conservative medical or palliative care. Finally, due to the 
observational design of this cohort study, it is impossible to study causal inference.
Previous reports on RKF have suggested to postpone kidney transplantation in patients on 
maintenance dialysis with certain types of underlying kidney disease associated with a high likelihood 
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guide management, we do not advocate postponing kidney transplantation in patients with kidney 
disease associated with a high likelihood of RKF, based on our current findings with aforementioned 
limitations or on other available literature on this subject to date.
In conclusion, our study shows that permanent discontinuation of maintenance dialysis in patients with 
ESKD is an uncommon event, which occurs across a variety of underlying kidney pathology, although 
patients with certain types of kidney disease have the highest likelihood of RKF in this setting. In 
addition, sustained RKF is not necessarily an early event. Therefore, although rare, clinicians should 
be vigilant of the occurrence of RKF, even in patients who have been treated with maintenance 
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Table 1. Characteristics of patients on maintenance dialysis who started treatment between 1997 












Females 163,188 (37.0) 2,239 (41.0) 761 (34.7)
Males 277,808 (63.0) 3,226 (59.0) 1,431 (65.3) <0.001
Age at onset in years, median (IQR) 67.9 (55.8 - 76.5) 69.7 (59.6 - 77.0) 64.2 (52.0 - 72.2) <0.001
Age categories, N (%)
20-39y 33,878 (7.7) 260 (4.8) 239 (10.9) <0.001
40-59y 10,8671 (24.6) 1,131 (20.7) 628 (28.6) <0.001
60-79y 232,786 (52.8) 3,215 (58.8) 1,189 (54.2) <0.001
80-100y 65,661 (14.9) 859 (15.7) 136 (6.2) <0.001
PRD group, N (%)
Diabetes mellitus type 1 and 2 106,100 (24.1) 603 (11.0) 374 (17.1) <0.001
Cause unknown or missing 87,772 (19.9) 1,247 (22.8) 325 (14.8) <0.001
Hypertension 63,366 (14.4) 530 (9.7) 299 (13.6) <0.001
Cystic kidney disease 28,925 (6.6) 17 (0.3) 40 (1.8) <0.001
Glomerulonephritis 28,570 (6.5) 442 (8.1) 211 (9.6) 0.029
Pyelonephritis/infectious 24,718 (5.6) 295 (5.4) 136 (6.2) 0.166
Renovascular disease 18,553 (4.2) 291 (5.3) 101 (4.6) 0.198
IgA nephropathy 13,300 (3.0) 120 (2.2) 53 (2.4) 0.554
Paraproteinemia 11,461 (2.6) 451 (8.3) 107 (4.9) <0.001
TIN and drug-induced 11,277 (2.6) 246 (4.5) 81 (3.7) 0.115
Vasculitis 9,514 (2.2) 295 (5.4) 164 (7.5) <0.001
FSGS with nephrotic syndrome 7,456 (1.7) 40 (0.7) 29 (1.3) 0.013
Ischaemic renal disease/cholesterol embolism 6,440 (1.5) 158 (2.9) 53 (2.4) 0.253
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Congenital kidney disease 4,926 (1.1) 14 (0.3) 24 (1.1) <0.001
Membraneous nephropathy 4,114 (0.9) 44 (0.8) 25 (1.1) 0.160
Miscellaneous 3,689 (0.8) 70 (1.3) 32 (1.5) 0.537
Tubular necrosis (irreversible) or cortical necrosis 3,450 (0.8) 404 (7.4) 86 (3.9) <0.001
HUS 1,167 (0.3) 95 (1.7) 30 (1.4) 0.249
Systemic sclerosis 546 (0.1) 50 (0.9) 7 (0.3) 0.006
KRT modality at day 91, N (%)
HD 361,549 (82.0) 4,821 (88.2) 1,707 (77.9) <0.001
PD 79,447 (18.0) 644 (11.8) 485 (22.1) <0.001
KRT modality at RKF, N (%)
HD 4,702 (86.0) 1,680 (76.6) <0.001
PD 753 (13.8) 508 (23.2) <0.001
Unknown 10 (0.2) 4 (0.2) 0.996
Duration of RKF, N (%)
30-90 days 264 (12.0)
90-365 days 590 (26.9)
1-2 years 455 (20.8)
2-5 years 614 (28.0)
>5 years 269 (12.3)




PRD: primary renal disease; KRT: kidney replacement therapy; HD: hemodialysis; PD: peritoneal dialysis; FSGS: focal 
segmental glomerulosclerosis; HUS: hemolytic uremic syndrome; TIN: tubulo-interstitial nephritis; RKF: recovery of kidney 
function; IQR: interquartile range. Paraproteinemia includes multiple myeloma, light chain nephropathy and amyloidosis. 
For categorical variables p-values were calculated with chi-square tests, for continuous variables the Wilcoxon test was 
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Table 2. Unadjusted and adjusted hazard ratios with 95% CI for 1) all recovery of kidney function (RKF) and 2) sustained RKF
All RKF Sustained RKF










Adjusted HR (95% CI)
Sex
Male 277,808 4607 (1.7) 1 (ref) 1 (ref) 3185 (1.1) 1 (ref) 1 (ref)
Female 163,188 2954 (1.8) 1.08 (1.03-1.13) 1.04 (1-1.09) 2201 (1.3) 1.17 (1.11-1.23) 1.13 (1.07-1.19)
KRT modality at day 91
HD 361,549 6450 (1.8) 1.27 (1.19-1.35) 1.21 (1.13-1.29) 4757 (1.3) 1.65 (1.52-1.79) 1.50 (1.38-1.64)
PD 79,447 1111 (1.4) 1 (ref) 1 (ref) 629 (0.8) 1 (ref) 1 (ref)
Age start (years)
20-39 years 33,878 495 (1.5) 1 (ref) 1 (ref) 257 (0.8) 1 (ref) 1 (ref)
40-59 years 108,671 1735 (1.6) 1.02 (0.93-1.13) 1.18 (1.07-1.31) 1111 (1.0) 1.27 (1.11-1.45) 1.46 (1.27-1.67)
60-79 years 232,786 4342 (1.9) 1.21 (1.10-1.32) 1.27 (1.16-1.40) 3165 (1.4) 1.70 (1.50-1.93) 1.77 (1.55-2.02)
80-100 years 65,661 989 (1.5) 1.05 (0.94-1.17) 1.05 (0.94-1.18) 853 (1.3) 1.75 (1.52-2.01) 1.69 (1.46-1.95)
PRD group
Diabetes mellitus type 1 and 2 106,100 965 (0.9) 1 (ref) 1 (ref) 592 (0.6) 1 (ref) 1 (ref)
Cause unknown or missing 87,772 1552 (1.8) 2.01 (1.86-2.18) 2.28 (2.10-2.47) 1230 (1.4) 2.60 (2.36-2.87) 2.90 (2.63-3.20)
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Cystic kidney disease 28,925 57 (0.2) 0.22 (0.17-0.28) 0.22 (0.17-0.29) 17 (0.1) 0.10 (0.06-0.17) 0.11 (0.07-0.19)
Glomerulonephritis 28,570 650 (2.3) 2.51 (2.27-2.77) 2.75 (2.48-3.04) 441 (1.5) 2.78 (2.46-3.14) 3.25 (2.87-3.68)
Pyelonephritis/ infectious 24,718 419 (1.7) 1.85 (1.65-2.07) 2.07 (1.84-2.32) 284 (1.1) 2.04 (1.77-2.35) 2.31 (2.01-2.66)
Renovascular disease 18,553 381 (2.1) 2.33 (2.07-2.63) 2.09 (1.85-2.36) 283 (1.5) 2.82 (2.45-3.25) 2.42 (2.09-2.80)
IgA nephropathy 13,300 171 (1.3) 1.50 (1.28-1.77) 1.61 (1.36-1.89) 118 (0.9) 1.69 (1.39-2.06) 2.00 (1.64-2.44)
Paraproteinemia 11,461 553 (4.8) 6.37 (5.73-7.07) 6.22 (5.60-6.91) 447 (3.9) 8.35 (7.39-9.45) 7.96 (7.04-9.01)
TIN and drug-induced 11,277 326 (2.9) 3.25 (2.86-3.68) 3.03 (2.67-3.43) 245 (2.2) 3.98 (3.43-4.62) 3.77 (3.24-4.37)
Vasculitis 9,514 454 (4.8) 5.38 (4.81-6.01) 5.37 (4.80-6.01) 291 (3.1) 5.62 (4.88-6.47) 5.72 (4.96-6.59)
FSGS with nephrotic syndrome 7,456 69 (0.9) 1.01 (0.79-1.30) 1.06 (0.83-1.36) 40 (0.5) 0.96 (0.70-1.32) 1.07 (0.77-1.47)
Ischaemic renal disease/cholesterol embolism 6,440 207 (3.2) 3.69 (3.18-4.29) 3.51 (3.00-4.09) 154 (2.4) 4.47 (3.74-5.34) 4.15 (3.46-4.98)
Kidney tumour/trauma/loss 5,652 67 (1.2) 1.34 (1.05-1.72) 1.27 (0.99-1.63) 52 (0.9) 1.70 (1.28-2.26) 1.56 (1.17-2.07)
Congenital kidney disease 4,926 38 (0.8) 0.87 (0.63-1.20) 0.96 (0.70-1.34) 14 (0.3) 0.52 (0.31-0.89) 0.67 (0.39-1.14)
Membraneous nephropathy 4,114 67 (1.6) 1.75 (1.37-2.24) 1.91 (1.49-2.45) 43 (1.0) 1.83 (1.35-2.50) 2.02 (1.48-2.76)
Miscellaneous 3,689 100 (2.7) 3.06 (2.49-3.76) 3.14 (2.56-3.86) 68 (1.8) 3.39 (2.64-4.35) 3.63 (2.82-4.67)
Tubular necrosis (irreversible) or cortical necrosis 3,450 485 (14.1) 18.44 (16.54-20.57) 15.87 (14.21-17.73) 400 (11.6) 24.71 (21.76-28.05) 20.35 (17.89-23.14)
HUS 1,167 124 (10.6) 12.52 (10.39-15.10) 12.44 (10.29-15.04) 94 (8.1) 15.46 (12.43-19.21) 17.31 (13.88-21.59)
Systemic sclerosis 546 57 (10.4) 12.92 (9.89-16.88) 12.76 (9.76-16.69) 50 (9.2) 18.43 (13.81-24.59) 18.50 (13.84-24.72)
Onset of KRT
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2002-2006 98,103 1576 (1.6) 1.2 (1.10-1.31) 1.37 (1.26-1.49) 1026 (1.0) 1.42 (1.27-1.59) 1.57 (1.40-1.76)
2007-2011 133,838 2578 (1.9) 1.42 (1.31-1.54) 1.68 (1.55-1.83) 1782 (1.3) 1.79 (1.61-1.99) 2.04 (1.83-2.27)
2012-2016 150,013 2630 (1.8) 1.40 (1.29-1.51) 1.67 (1.53-1.81) 2150 (1.4) 2.07 (1.87-2.30) 2.38 (2.14-2.65)
Hazard ratio (HR) adjusted for age at onset of dialysis, sex, year of dialysis onset, treatment modality at day 91, underlying kidney disease (PRD) and country of residence; 
KRT: kidney replacement therapy; HD: hemodialysis; PD: peritoneal dialysis; PRD: primary renal disease; FSGS: focal segmental glomerulosclerosis; HUS: hemolytic uremic syndrome; TIN: 
tubulo-interstitial nephritis. Patient numbers differ slightly from those shown in Table 1, as the Cox-regression analyses included only patients with a RKF within five years after initiation of 
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FIGURE 1: Cumulative incidence of recovery of kidney function and other competing events during 






/ndt/advance-article/doi/10.1093/ndt/gfaa368/6045961 by guest on 30 M
arch 2021
30
FIGURE 2A AND B: Time between day 91 of dialysis treatment and sustained and non-sustained 
recovery of kidney function (RKF) displayed as total patient numbers (A) and as a percentage of all 
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FIGURE 3: Incidence of recovery of kidney function with annual percent change within two years 
after initiation of maintenance dialysis.
Incidence of recovery of kidney function (RKF) within two years after start of maintenance dialysis as 
a percentage of the total incident population on maintenance dialysis in that year. This includes 
patients with both sustained and non-sustained RKF. Inclusion was limited to the years 1997-2016 and 
follow-up to 31 December 2017 in order to ensure sufficient follow-up time for RKF to occur, as 90% 
of all recoveries occurred within 2 years. Only data from registries providing data for the complete 
time-period were included: Austria, Dutch-speaking Belgium, French-speaking Belgium, Denmark, 
Finland, Greece, Iceland, the Netherlands, Norway, the Spanish regional renal registries of Andalusia, 
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FIGURE 4: Cumulative incidence of death, kidney transplantation and dialysis as competing events 
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